文献速递免疫规划传染病防控与疫情报告

皮下接种减毒鼠疫耶尔森菌活疫苗

Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine.
PubMed 文献 · Vaccine · 2020-01-18

小鼠单次皮下注射减毒鼠疫耶尔森菌VTnF1株,剂量依赖性地诱导抗体产生;107 CFU剂量(比口服途径少10倍)引起轻度皮肤反应,对腺鼠疫保护100%、对肺鼠疫保护80%,细菌在淋巴结和脾脏中快速清除。

要点

  • 单次皮下注射VTnF1可达107 CFU剂量,比口服途径少10倍。
  • 107 CFU皮下接种对腺鼠疫保护100%、对肺鼠疫保护80%。
  • 迁移至淋巴结和脾脏的细菌被快速清除,粪便中未检出细菌。

核心结论

  • 皮下注射VTnF1是当自然传播和人类肠道反应性成为限制时的良好替代方案。

研究设计与样本

  • 小鼠模型,评估单次皮下注射减毒鼠疫耶尔森菌VTnF1株的免疫保护效果。

主要发现

  • 单次皮下剂量高达108 CFU诱导剂量依赖性抗体产生。
  • 107 CFU剂量(比口服途径少10倍)引起轻度皮肤反应,对腺鼠疫保护100%、对肺鼠疫保护80%。
  • 迁移至淋巴结和脾脏的细菌被快速清除,粪便中未检出细菌。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A single oral inoculation to mice of the live attenuated Yersinia pseudotuberculosis VTnF1 strain producing an F1 pseudocapsule protects against bubonic and pneumonic plague. However oral vaccination can fail in humans exposed to frequent intestinal infections. We evaluated in mice the efficacy of subcutaneous vaccine injection as an alternative way to induce protective immunity, while reducing the dose and avoiding strain release in nature. A single subcutaneous dose of up to 108 CFU induced dose-dependent antibody production. At the dose of 107 CFU, i.e. 10 times less than via the oral route, it caused a modest skin reaction and protected 100% against bubonic and 80% against pneumonic plague, caused by high doses of Yersinia pestis. Bacteria migrating to lymph nodes and spleen, but not feces, were rapidly eliminated. Thus, subcutaneous injection of VTnF1 would represent a good alternative when dissemination in nature and human intestinal responsiveness are limitations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Derbise A, Guillas C, Gerke C, et al. Subcutaneous vaccination with a live attenuated Yersinia pseudotuberculosis plague vaccine. Vaccine. 2020. PMID: 31964555. doi:10.1016/j.vaccine.2020.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。